Immunovant, Inc.
Financial highlights
| Metric | FY 03/31/26 | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $456.7M | $360.9M | $212.9M | $160.3M | $101.8M |
| Operating expenses | $532.9M | $438.2M | $282.7M | $218.3M | $156.0M |
| Pretax income | -$505.4M | -$412.9M | -$258.8M | -$211.0M | -$156.8M |
| Income tax expense | $215,000 | $891,000 | $567,000 | $9,000 | -$84,000 |
| Net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M | -$156.7M |
| Balance Sheet | |||||
| Cash and equivalents | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M |
| Current assets | $948.8M | $767.7M | $665.8M | $404.3M | $512.9M |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M |
| Current liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $44.5M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M |
| Stockholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M |
| Depreciation and amortization | $409,000 | $377,000 | $231,000 | $193,000 | $126,000 |
| Stock-based compensation | $55.7M | $49.5M | $41.1M | $32.3M | $34.2M |
| Capital expenditure | $8,000 | $759,000 | $360,000 | $197,000 | $254,000 |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M |
Shares outstanding 203.5M · Free float 96.3%
Annual filing data through FY ended March 31, 2026; float as of July 4, 2026.